Why is Autolus Therapeutics plc (AUTL) One of the Best Stocks Under $5 With Highest Upside Potential?

Core Insights - Autolus Therapeutics plc (NASDAQ:AUTL) is recognized as a promising stock under $5 with significant upside potential, receiving a Buy rating from Needham analyst Gil Blum, who set a price target of $10 based on positive clinical data [1][2] Clinical Data and Developments - At the American College of Rheumatology Convergence 2025, Autolus presented updates from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE), indicating that the obe-cel treatment is well tolerated with no instances of ICANS or high-grade CRS [2] - The study reported that 83% of patients achieved the definition of remission in SLE (DORIS), and 50% exhibited complete renal response (CRR), with all remissions ongoing and no evidence of disease activity at a median follow-up of 8.9 months [2] - The company is on track to initiate dosing for the first patient in the Phase 2 trial for lupus nephritis (LN) by the end of the year [2] Expert Commentary - Dr. Maria Leandro, a consultant rheumatologist, highlighted that the CARLYSLE study data suggests that obe-cel could significantly impact patients with severe refractory SLE who lack approved treatment options, noting durable responses and an encouraging safety profile [2] Company Overview - Autolus Therapeutics is a clinical-stage biopharmaceutical company based in the UK, focusing on developing programmed T cell therapies for autoimmune diseases and cancer, particularly through chimeric antigen receptor (CAR) T cell therapy [2]